The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications

Herder, C. and Dalmas, E. and Boni-Schnetzler, M. and Donath, M. Y.. (2015) The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications. Trends in Endocrinology and Metabolism, 26 (10). pp. 551-563.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/61699/

Downloads: Statistics Overview


Patients with type 2 diabetes (T2D) exhibit chronic activation of the innate immune system in pancreatic islets, in insulin-sensitive tissues, and at sites of diabetic complications. This results from a pathological response to overnutrition and physical inactivity seen in genetically predisposed individuals. Processes mediated by the proinflammatory cytokine interleukin-1 (IL-1) link obesity and dyslipidemia and have implicated IL-1beta in T2D and related cardiovascular complications. Epidemiological, molecular, and animal studies have now assigned a central role for IL-1beta in driving tissue inflammation during metabolic stress. Proof-of-concept clinical studies have validated IL-1beta as a target to improve insulin production and action in patients with T2D. Large ongoing clinical trials will address the potential of IL-1 antagonism to prevent cardiovascular and other related complications.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Diabetes Research (Donath)
UniBasel Contributors:Donath, Marc
Item Type:Article, refereed
Article Subtype:Further Journal Contribution
Note:Publication type according to Uni Basel Research Database: Journal item
Identification Number:
Last Modified:01 Nov 2018 19:16
Deposited On:22 Oct 2018 15:36

Repository Staff Only: item control page